Table 1 Characteristics of the patients at baseline and during follow-up by lipids treatment group
Characteristics | Total | Treatment | P value | |
|---|---|---|---|---|
Fenofibrate | Placebo | |||
N | 5194 | 2615 | 2579 | |
At baseline | ||||
Age, year | 62.7 (6.6) | 62.7 (6.5) | 62.8 (6.6) | 0.827 |
Male, No. (%) | 3602 (69.3) | 1815 (69.4) | 1787 (69.3) | 0.927 |
BMI, kg/m^2 | 32.3 (5.3) | 32.2 (5.3) | 32.4 (5.4) | 0.352 |
SBP, mmHg | 133.8 (17.7) | 133.8 (17.5) | 133.9 (17.9) | 0.850 |
DBP, mmHg | 73.9 (10.7) | 73.8 (10.6) | 74.0 (10.9) | 0.546 |
Current smoking, No. (%) | 741 (14.3) | 382 (14.6) | 359 (13.9) | 0.478 |
Current drinking, No. (%) | 1279 (24.6) | 649 (24.8) | 630 (24.4) | 0.732 |
Diabetes duration, year | 10.6 (7.4) | 10.6 (7.3) | 10.7 (7.5) | 0.767 |
Race/ethnicity, No. (%) | 0.289 | |||
White | 3417 (65.8) | 1729 (66.1) | 1688 (65.5) | |
Hispanic | 380 (7.3) | 200 (7.6) | 180 (7.0) | |
Black | 758 (14.6) | 359 (13.7) | 399 (15.5) | |
Other | 639 (12.3) | 327 (12.5) | 312 (12.1) | |
Intensive glycemia, No. (%) | 2584 (49.7) | 1294 (49.5) | 1290 (50.0) | 0.699 |
Laboratory results | ||||
HDL-C, mg/dL | 38.1 (7.7) | 38.0 (7.8) | 38.2 (7.7) | 0.278 |
LDL-C, mg/dL | 100.5 (30.7) | 99.9 (30.4) | 101.1 (31.1) | 0.156 |
Total cholesterol, mg/dL | 175.2 (37.4) | 174.8 (36.8) | 175.7 (37.9) | 0.402 |
Triglycerides, mg/dL | 188.2 (112.9) | 190 (111.4) | 186.3 (114.4) | 0.244 |
HbA1c, % | 8.3 (1.0) | 8.3 (1.0) | 8.3 (1.0) | 0.468 |
eGFR, mL/min/1.73 m^2 | 90.6 (25.7) | 90.6 (24.7) | 90.5 (26.6) | 0.918 |
During the first two years | ||||
LDL-C MEAN, mg/dL | 92.0 (20.8) | 91.4 (20.7) | 92.6 (20.9) | 0.034 |
HDL-C MEAN, mg/dL | 39.7 (8.2) | 40.1 (8.7) | 39.3 (7.7) | < 0.001 |
HDL-C CV, % | 10.7 (7.0) | 12.1 (8.5) | 9.4 (4.7) | < 0.001 |
TG MEAN, mg/dL | 169.9 (96.8) | 156.2 (89.2) | 183.7 (102.2) | < 0.001 |
TG CV, % | 29.0 (15.0) | 30.7 (15.8) | 27.3 (13.8) | < 0.001 |
HbA1c MEAN, % | 7.1 (0.9) | 7.2 (0.9) | 7.1 (0.9) | 0.035 |
HbA1c CV, % | 6.7 (4.5) | 7.0 (4.6) | 6.4 (4.3) | < 0.001 |